Skip to content Skip to footer
Subscribe Now
VIEWPOINTS_James Graham_2023
VIEWPOINTS

James Graham, CEO of Recce Pharmaceuticals Shares Insights from the Expansion and Acceleration of Clinical Programs

Shots:James gave an overview of the timeline of Recce Pharmaceuticals' clinical programs with several significant data read-outs in 2022 and 2023He emphasized the study design and results from the different infectious disease clinical and preclinical programs in its product portfolioThe interview highlights how the development and commercialization of New Classes of Synthetic Anti-Infectives…
April 18, 2023

Read more

Viewpoints_James Graham
VIEWPOINTS

PharmaShots Interview: Recce Pharmaceuticals’ James Graham Shares Insight on the P-I/II Clinical Trial of RECCE 327 (R327) for Infected Burn Wounds

In an interview with PharmaShots, James Graham, CEO of Recce Pharmaceuticals shared his views on the multiple patient dosing in P-I/II clinical trial of RECCE 327 (R327) for the treatment of infected burn wounds.Shots:The multiple patients have been dosed in P-I/II trial evaluates the effectiveness & safety of RECCE 327 in 30 patients (10 will receive RECCE 327…
September 14, 2021

Read more